PMID- 25144513
OWN - NLM
STAT- MEDLINE
DCOM- 20150610
LR  - 20151119
IS  - 1473-6543 (Electronic)
IS  - 1062-4821 (Linking)
VI  - 23
IP  - 6
DP  - 2014 Nov
TI  - Plasma exchange in antineutrophil cytoplasm antibody-associated vasculitis.
PG  - 555-9
LID - 10.1097/MNH.0000000000000058 [doi]
AB  - PURPOSE OF REVIEW: This article reviews the use of plasma exchange for the 
      treatment of antineutrophil cytoplasm antibody-associated vasculitis (AAV) with a 
      focus on current controversies and knowledge gaps. RECENT FINDINGS: Experimental 
      evidence suggesting that antineutrophil cytoplasm antibodies are pathogenic 
      continues to evolve and support the theory that rapid removal of antineutrophil 
      cytoplasm antibody with plasma exchange may be beneficial. Although early, small 
      trials of plasma exchange in rapidly progressive glomerulonephritis and 
      vasculitis suggested that plasma exchange may improve a patient's potential for 
      renal recovery, more recent analyses have called the net benefit of plasma 
      exchange into question. Furthermore, there is uncertainty as to whether plasma 
      exchange is beneficial to patients with particular organ manifestations of their 
      AAV (e.g., lung hemorrhage). SUMMARY: Whether plasma exchange should be used 
      routinely in antineutrophil cytoplasm antibody-associated vasculitis, in patients 
      with certain manifestations or severity of disease only, or not at all, remains 
      unclear. Given that plasma exchange is expensive and invasive, further research 
      to resolve these uncertainties is required.
FAU - Walsh, Michael
AU  - Walsh M
AD  - aDepartment of Medicine bDepartment of Clinical Epidemiology and Biostatistics, 
      McMaster University cPopulation Health Research Institute, McMaster 
      University/Hamilton Health Sciences, Hamilton, Canada.
LA  - eng
GR  - Canadian Institutes of Health Research/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Curr Opin Nephrol Hypertens
JT  - Current opinion in nephrology and hypertension
JID - 9303753
RN  - 0 (Antibodies, Antineutrophil Cytoplasmic)
RN  - 0 (Biomarkers)
SB  - IM
MH  - Animals
MH  - Anti-Neutrophil Cytoplasmic Antibody-Associated 
      Vasculitis/blood/diagnosis/immunology/*therapy
MH  - Antibodies, Antineutrophil Cytoplasmic/*blood
MH  - Biomarkers/blood
MH  - Disease Progression
MH  - Humans
MH  - *Plasma Exchange
MH  - Treatment Outcome
EDAT- 2014/08/22 06:00
MHDA- 2015/06/11 06:00
CRDT- 2014/08/22 06:00
PHST- 2014/08/22 06:00 [entrez]
PHST- 2014/08/22 06:00 [pubmed]
PHST- 2015/06/11 06:00 [medline]
AID - 10.1097/MNH.0000000000000058 [doi]
PST - ppublish
SO  - Curr Opin Nephrol Hypertens. 2014 Nov;23(6):555-9. doi: 
      10.1097/MNH.0000000000000058.